ClinicalTrials.gg
TerminatedNCT04569084Updated Jul 20, 2026Results posted

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

A Phase 3 interventional study of MT-1186 and Placebo in ALS, sponsored by Shionogi. Terminated at 95 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Why this study was terminated
Futility was met.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:

02

Conditions studied

  • ALS
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Subjects must provide a signed and dated form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.
  2. Subjects will be male or female, ≥ 18 to 75 years of age at the time the ICF is signed.
  3. Subjects will be diagnosed with Definite ALS or Probable ALS according to the El Escorial revised criteria for the diagnosis of ALS.
  4. Subjects with a baseline score ≥ 2 points on each individual item of the ALSFRS- R at screening and baseline visits.
  5. Subjects have a screening and baseline %forced vital capacity (FVC) ≥ 70%.
  6. Subjects with 1- to 4-point decline for 8 weeks (±7 days) in ALSFRS-R total score between screening and baseline visits.
  7. Subjects whose first symptom of ALS has occurred within 2 years of providing written informed consent.

Exclusion Criteria:

Exclusions Related to Primary Diagnosis

  1. Subjects with a history of spinal surgery after the onset of ALS, such as surgery for cervical spondylosis or a herniated disc, or plans for such surgery during the study period.

    Exclusions Related to Other Neurological Disorders (including, but not limited to the following)

  2. Subjects with the possibility that the current symptoms may be symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy, cannot be ruled out.

    Exclusions Related to General Health or Concomitant Conditions

  3. Subjects undergoing treatment for a .
  4. Subjects with a complication that could have a significant effect on efficacy evaluations, such as Parkinson's disease or syndrome, schizophrenia, bipolar disorder, and dementia.
  5. Subjects who have the presence or history of any (CS) disease (except ALS) that could interfere with the objectives of the study (the assessment of safety and efficacy) or the safety of the subject, as judged by the Investigator.
  6. Subjects who are female, of , and pregnant (a positive pregnancy test) or lactating at the screening visit (Visit 1).
  7. Subjects of childbearing potential unwilling to use acceptable method of from the screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period.
  8. Subjects who have a significant risk of suicidality. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the 3 months before the screening visit.
  9. Subjects who have (ALT) or aspartate aminotransferase (AST) elevations greater than 2 times the (ULN) at screening.
  10. Subjects with a (GFR) \< 30 mL/Min Per 1.73 m2 at screening, using the Larsson Equation.

    Exclusions Related to Medications

  11. Subjects with history of to edaravone, any of the additives or inactive ingredients of edaravone, or sulfites.
  12. Subjects with hereditary problems of fructose intolerance (eg, fructose, sucrose, invert sugar, and sorbitol).
  13. Subjects who participated in another study and were administered an product within 1 month or 5 half-lives of the investigational agent, whichever is longer, before providing informed consent for the present study.
  14. Subjects who have received any previous treatment with edaravone.
  15. Subjects who have received stem cell therapy.
  16. Subjects who are unable to take their medications orally at baseline (Visit 2).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    MT-1186

    Drug: MT-1186

  • Experimental
    MT-1186 and Placebo

    Drug: MT-1186 · Drug: Placebo

Interventions

  • DrugMT-1186

    Oral edaravone

    Also known as: Oral edaravone

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. CAFS Score at Week 48

    CAFS ranks patients' clinical outcomes based on survival time and change in the ALSFRS-R score. To calculate a patient's CAFS, each patient is compared individually to all other patients in the study. The summary score for each patient is the sum of the comparisons ( 1, 0, 1) against all other patients. After that, patients' summary scores are ranked. The CAFS rank is 1-383 and a higher CAFS rank indicates a better outcome than does a lower CAFS. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.

    Time frame: up to 48 Weeks

Secondary outcomes

  1. Change From Baseline in % Slow Vital Capacity (SVC) at Week 48

    SVC measurements will be conducted in clinic at around the same time of day where possible with the subject in sitting upright position. Subjects should make at least 3 attempts to generate acceptable and reproducible SVC data. The highest value was selected and recorded.

    Time frame: up to 48 Weeks

  2. Change From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ)40 at Week 48

    The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).

    Time frame: up to 48 Weeks

  3. Time to Death, Tracheostomy or Permanent Assisted Mechanical Ventilation (≥ 23 Hours/Day)

    Time frame: up to 48 Weeks

  4. Time to Death or PAMV (≥ 23 Hours/Day)

    Time frame: up to 48 Weeks

  5. Time to Death

    Time frame: up to 48 Weeks

07

Results

Posted Mar 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
Started192192
Completed125121
Not completed6771
Withdrew: Adverse event1014
Withdrew: Death23
Withdrew: Lost to follow-up11
Withdrew: Physician decision33
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject2021
Withdrew: Study terminated by sponsor2623
Withdrew: Other35

Outcome measures

PrimaryCAFS Score at Week 48

CAFS ranks patients' clinical outcomes based on survival time and change in the ALSFRS-R score. To calculate a patient's CAFS, each patient is compared individually to all other patients in the study. The summary score for each patient is the sum of the comparisons ( 1, 0, 1) against all other patients. After that, patients' summary scores are ranked. The CAFS rank is 1-383 and a higher CAFS rank indicates a better outcome than does a lower CAFS. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.

Time frame:
up to 48 Weeks
Reported as:
Mean · Units on a scale
CAFS Score at Week 48
Units on a scaleEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
CAFS Score at Week 48187.2 (4 to 383)184.2 (1 to 383)
Statistical analysis
  • Edaravone 105 mg (Once Daily) vs Edaravone 105mg (2 Weeks On/Off ) · ANCOVA · p = 0.777
SecondaryChange From Baseline in % Slow Vital Capacity (SVC) at Week 48

SVC measurements will be conducted in clinic at around the same time of day where possible with the subject in sitting upright position. Subjects should make at least 3 attempts to generate acceptable and reproducible SVC data. The highest value was selected and recorded.

Time frame:
up to 48 Weeks
Reported as:
Least squares mean · percentage of SVC
Change From Baseline in % Slow Vital Capacity (SVC) at Week 48
percentage of SVCEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
Change From Baseline in % Slow Vital Capacity (SVC) at Week 48-26.94 ± 2.45-22.15 ± 2.48
Statistical analysis
  • Edaravone 105 mg (Once Daily) vs Edaravone 105mg (2 Weeks On/Off ) · Mixed Model for Repeated Measures (MMRM) · p = 0.169
SecondaryChange From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ)40 at Week 48

The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).

Time frame:
up to 48 Weeks
Reported as:
Least squares mean · Point
Change From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ)40 at Week 48
PointEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
Change From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ)40 at Week 482.35 ± 0.251.79 ± 0.25
SecondaryTime to Death, Tracheostomy or Permanent Assisted Mechanical Ventilation (≥ 23 Hours/Day)
Time frame:
up to 48 Weeks
Reported as:
Mean · Months
Time to Death, Tracheostomy or Permanent Assisted Mechanical Ventilation (≥ 23 Hours/Day)
MonthsEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
Time to Death, Tracheostomy or Permanent Assisted Mechanical Ventilation (≥ 23 Hours/Day)NA (NA to NA)NA (NA to NA)
SecondaryTime to Death or PAMV (≥ 23 Hours/Day)
Time frame:
up to 48 Weeks
Reported as:
Median · Months
Time to Death or PAMV (≥ 23 Hours/Day)
MonthsEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
Time to Death or PAMV (≥ 23 Hours/Day)NA (NA to NA)NA (NA to NA)
SecondaryTime to Death
Time frame:
up to 48 Weeks
Reported as:
Median · Months
Time to Death
MonthsEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
Time to DeathNA (NA to NA)NA (NA to NA)

Adverse events

Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edaravone 105 mg (Once Daily)9/192 (4.7%)52/192 (27.1%)118/192 (61.5%)
Edaravone 105mg (2 Weeks On/Off )16/192 (8.3%)55/191 (28.8%)131/191 (68.6%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
DysphagiaGastrointestinal disorders16/19215/191
Respiratory failureRespiratory, thoracic and mediastinal disorders9/19210/191
Amyotrophic lateral sclerosisNervous system disorders1/1925/191
Respiratory disorderRespiratory, thoracic and mediastinal disorders2/1925/191
COVID-19Infections and infestations4/1924/191
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/1923/191
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1922/191
GastrostomySurgical and medical procedures3/1920/191
Cardiac arrestCardiac disorders1/1922/191
SyncopeNervous system disorders1/1922/191
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEdaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )
FallInjury, poisoning and procedural complications36/19234/191
ConstipationGastrointestinal disorders24/19227/191
COVID-19Infections and infestations24/19226/191
Back painMusculoskeletal and connective tissue disorders8/19220/191
DiarrhoeaGastrointestinal disorders20/19214/191
ContusionInjury, poisoning and procedural complications17/19214/191
Muscular weaknessMusculoskeletal and connective tissue disorders15/19213/191
HeadacheNervous system disorders15/1929/191
CoughRespiratory, thoracic and mediastinal disorders15/19211/191
InsomniaPsychiatric disorders11/19214/191

Baseline characteristics

Age, Customized
Age, Customized(Participants)Edaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )Total
18-64 years134122256
65-84 years5870128
Sex: Female, Male
Sex: Female, Male(Participants)Edaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )Total
Female6970139
Male123122245
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Edaravone 105 mg (Once Daily)Edaravone 105mg (2 Weeks On/Off )Total
Hispanic or Latino9514
Not Hispanic or Latino183187370
Unknown or Not Reported000
08

Study locations

95 sites
  • St. Joseph's Hospital and Medical Center (SJHMC)
    Phoenix, Arizona 85013, United States
  • HonorHealth Neurology
    Scottsdale, Arizona 85251, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • UCSD Medical Center
    La Jolla, California 92037-0897, United States
  • Loma Linda University Health Care - Department of Neurology
    Loma Linda, California 92354, United States
  • University California Los Angeles Medical Center (UCLA)
    Los Angeles, California 90095, United States
  • University of California Irvine (UCI) Health - Women's Healthcare Center
    Orange, California 92868, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • UF Health Cancer Center
    Gainesville, Florida 32610-3633, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • University of South Florida (USF) - Carol and Frank Morsani Center for Advanced Health Care (CAHC)
    Tampa, Florida 33616, United States
  • Emory University - School of Medicine
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611-2605, United States
  • Ochsner Center for Primary Care and Wellness
    Jefferson, Louisiana 70121, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Lahey Hospital
    Burlington, Massachusetts 01805, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Neurology Associates, P.C. - Lincoln
    Lincoln, Nebraska 68506-2960, United States
  • Las Vegas Clinic
    Las Vegas, Nevada 89145, United States
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University, Jefferson Weinberg ALS Center
    Philadelphia, Pennsylvania 19107, United States
  • Lewis Katz School of Medicine at Temple University
    Philadelphia, Pennsylvania 19140, United States
  • University Of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15261, United States
  • Wesley Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
  • Austin Neuromuscular Center
    Austin, Texas 78756, United States
  • Nerve And Muscle Center Of Texas
    Houston, Texas 77019, United States
  • The University of Vermont (UVM) and UVM Medical Center National ALS Center of Excellence
    Burlington, Vermont 05401-3456, United States
  • Sentara Neurology Specialists
    Virginia Beach, Virginia 23456, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • St. Luke's Rehabilitation Institute
    Spokane, Washington 99202, United States
  • West Virginia University School of Medicine (WVUSoM) - Movement Disorder Clinic
    Morgantown, West Virginia 26506-9180, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM)
    Edmonton, Alberta T6G 2B7, Canada
  • Regional Health Authority B
    Fredericton, New Brunswick E3B 0C7, Canada
  • Health Science Center Mcmaster University
    Hamilton, Ontario L8P 1H1, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Odette Cancer Center-Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Recherche Sepmus, Inc
    Greenfield Park, Quebec J4V 2J2, Canada
  • Centre Hospitalier De L'Universite De Montreal (Chum) Notre-Dame Hospital
    Montreal, Quebec H2L 4M1, Canada
  • Montreal Neurological Institute And Hospital
    Montreal, Quebec H3A 2B4, Canada
  • CHU de Quebec-Hopital-Enfant-Jesus
    Québec, Quebec G1J 1Z4, Canada
  • Saskatoon City Hospital
    Saskatoon, Saskatchewan S7K 0M7, Canada
  • Universitaetsklinikum Wuerzburg
    Wuezburg, Germany 97080, Germany
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • UKRUB - Berufsgenossenschaftliches Universitatsklinikum Bergmannsheil GmbH - Medizinische Klinik III
    Bochum, North Rhine-Westphalia 44789, Germany
  • Charite Campus Virchow
    Berlin, 13353, Germany
  • Universitätsklinik Bonn-Motoneuronambulanz, Klinik und Poliklinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie
    Bonn, 53127, Germany
  • Georg-August-Universitaet Goettingen - Universitaetsmedizin Goettingen (UMG)
    Göttingen, 37075, Germany
  • Universitaetsklinikum Jena
    Jena, 86899, Germany
  • Klinikum Rechts der Isar der Technischen Universitaet Muenchen
    München, 81675, Germany
  • University Medical Center Rostock
    Rostock, 18147, Germany
  • Universitaets- und Rehabilitationskliniken Ulm
    Ulm, 89081, Germany
  • Deutsche Klinik fuer Diagnostik
    Wiesbaden, 65191, Germany
  • Universita degli Studi di Torino - Centro Regionale Esperto Per La Sclerosi Laterale Amiotrofica (CRESLA)
    Turin, Piedmont 10126, Italy
  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca Granda - Centro Clinico Nemo (Neuro Muscular Omnicentre)
    Milan, Italy, Italy
  • Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)
    Milan, 20132, Italy
  • Istituto Nazionale Neurologico Carlo Besta
    Milan, Italy, Italy
  • Istituto Auxologico Italiano - Istituto Di Ricovero e Cura a Carattere Scientifico - Istituto Scientifico Ospedale San Luca
    Modena, 41126, Italy
  • Centro SLA di Palermo
    Palermo, 90129, Italy
  • Policlinico A. Gemelli
    Roma, CAP 00168, Italy
  • National Hospital Organization Higashinagoya National Hospital
    Meito-ku, Nagoya-shi, Aichi-ken 465-8620, Japan
  • Nagoya University Hospital
    Showa-ku, Nagoya, Aichi-ken 466-8560, Japan
  • National Hospital Organization Chibahigashi National Hospital
    Chuo-ku, Chiba-shi, Chiba 260-8712, Japan
  • Murakami Karindoh Hospital
    Nishi-ku, Fukuoka-shi, Fukuoka 819-8585, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • Hiroshima University Hospital
    Minami-ku, Hiroshima-shi, Hiroshima 734-8551, Japan
  • National Hospital Organization Hokkaido Medical Center
    Sapporo, Hokkaido 063-0005, Japan
  • National Hospital Organization Iou National Hospital
    Kanazawa, Ishikawa-ken 920-0192, Japan
  • Kagawa University Hospital
    Miki-cho, Kita-gun, Kagawa-ken 761-0793, Japan
  • Yokohama City University Hospital
    Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004, Japan
  • Kitasato University Hospital
    Minami-ku, Sagamihara-city, Kanagawa 252-0375, Japan
  • National Hospital Organization Kumamoto Saishun Medical Center
    Koshi-shi, Kumamoto 861-1196, Japan
  • National Hospital Organization Utano National Hospital
    Ukyo-ku, Kyoto City, Kyoto 616-8255, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Niigata University Medical & Dental Hospital
    Asahimachidori, Chuo-ku, Niigata-shi, Niigata 951-8520, Japan
  • Kansai Electric Power Hospital
    Fukushima-ku, Osaka-shi, Osaka 553-0003, Japan
  • National Hospital Organization Osaka Toneyama Medical Center
    Toyonaka-shi, Osaka 560-8552, Japan
  • Saitama Neuropsychiatric Institute
    Chuo-ku, Saitama-shi, Saitama 338-8577, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga 520-2192, Japan
  • National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders
    Aoi-ku, Shizuoka-shi, Shizuoka 420-8688, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Tokyo Metropolitan Neurological Hospital
    Fuchū, Tokyo 183-0042, Japan
  • Teikyo University Hospital
    Itabashi-ku, Tokyo 173-8606, Japan
  • Toho University Omori Medical Center
    Ōta-ku, Tokyo 143-8541, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Chiba University Hospital
    Chiba, 260-8677, Japan
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Hanyang University Medical Center
    Seoul, 04763, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • University hospital Bern (Inselspital)
    Bern, Canton of Bern 3010, Switzerland
  • Hopitaux Universitaires de Geneve (HUG) (Hopital Cantonal)
    Geneva, 1205, Switzerland
  • Neurocenter of Southern Switzerland
    Lugano, 6903, Switzerland
  • Zentrumsleiter Muskelzentrum/ALS Clinic Kantonsspital St.Gallen Muskelzentrum/ALS Clinic
    Sankt Gallen, 9107, Switzerland
09

References and documents

Publications

  • Rothstein J, Genge A, De Silva S, Zinman L, Chum M, Chio A, Sobue G, Aoki M, Yoshino H, Doyu M, Selness D, Todorovic V, Sasson N, Hirai M, Takahashi F, Salah A, Wamil A, Apple S. Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02). Muscle Nerve. 2025 Sep;72(3):433-442. doi: 10.1002/mus.28448. Epub 2025 Jun 6. PubMed 40474686 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Sep 2023, 34 months.

Results were first posted in Mar 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Sep 29, 2020
StartActual
Nov 13, 2020
Primary completionActual
Sep 29, 2023
CompletionActual
Sep 29, 2023
Results first posted
Mar 27, 2025
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04569084
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Sep 29, 2020
Start date
Nov 13, 2020
Primary completion
Sep 29, 2023
Completion
Sep 29, 2023
Results posted
Mar 27, 2025
Last update
Jul 20, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion